Business Wire 14-Jun-2018 4:15 PM
Kadmon Holdings, Inc. (NYSE:KDMN) today announced the closing of its previously announced offerings of common stock for gross proceeds of approximately $113.2 million, which includes the full exercise of the underwriters' option to purchase additional shares.
Proceeds from the offerings will be used for preclinical and clinical development of Kadmon's lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes.
"This financing is a testament to the significant potential of KD025 in cGVHD and provides the resources that we believe will allow us to pursue regulatory approval in this indication," said Harlan W. Waksal, M.D., President and CEO at Kadmon. "In parallel, we will continue to advance our preclinical programs as part of our goal to help patients with unmet medical needs."
Closing occurred with respect to a total of 32,022,728 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, at an offering price of $3.30 per share (the "Offerings"). The Offerings consisted of an underwritten offering (the "Underwritten Offering") and a registered direct offering (the "Direct Offering") to certain institutional investors. The closing of the remaining 2,280,302 shares of common stock in the Direct Offering is expected to occur on or about June 26, 2018.
"The continued support of our top-tier investors, including Vivo Capital, Perceptive Advisors and Acuta Capital, complemented by the participation of new groups such as Invesco, Venrock Healthcare Capital Partners, EcoR1 Capital and others, provides Kadmon with a strong investor base that recognizes the value of our scientific and clinical progress," said Konstantin Poukalov, CFO at Kadmon.
Jefferies LLC acted as the sole book-running manager for the Underwritten Offering. H.C. Wainwright & Co., LLC acted as the lead manager for the Underwritten Offering.
The securities described above were offered pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (the "SEC") on January 10, 2018. The Offerings were conducted only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the Offerings have been filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the Underwritten Offering may also be obtained by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.
This news release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation, or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the closing of the Offerings and the anticipated use of proceeds of the Offerings. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors also include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii)the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel; (xx) our ability to achieve cost savings and other benefits from our efforts to streamline our operations and to not harm our business with such efforts; (xxi) our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; (xxii) statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance; (xxiii) litigation, including costs associated with prosecuting or defending pending or threatened claims and any adverse outcomes or settlements, whether or not covered by insurance; (xxiv) the use of proceeds from the Offerings; (xxv) the potential benefits of any of our product candidates being granted orphan drug designation; (xxvi) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; and/or (xxvii) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended, with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Limited Time Offer:
Claim your free copy of income expert Bryan Perry's new report:
My Top Monthly Dividend Payer (8% Dividend Yield)
You'll also receive Bryan Perry's weekly e-letter, Dividend Investing Weekly, at no cost, along with other associated financial content and special offers.